Skip to main content

Scientific Study Summary: BIOFIRE® Mycoplasma For Cell & Gene Therapy Samples

Two cell therapy and four bioproduction manufacturers evaluted the BIOFIRE® FILMARRAY® 2.0 system with up to 9 compendial mycoplasma strains in the presence of high density chimeric antigen receptor T (CAR T) or Chinese hamster ovary (CHO) cells.

Interested in the results in an easy-to-digest format? Complete the form below to access the scientific summary, which will be sent directly to your email after submission. By providing your information, you agree to receive additional emails from bioMérieux about mycoplasma testing.

To find out more about the management of your personal data and to exercise your rights, see our privacy policy.

Learn More About Our "Molecular Lab In A Pouch"

WEBPAGE

1-Hour In-House Mycoplasma Testing for Cell & Gene Therapies

1-Hour Mycoplasma Testing By Anyone, Anywhere, Anytime

GET THE FACTS

On-Demand Webinar

Regulatory Submission Strategy for Implementation and Validation of a New PCR-Based Technology for Mycoplasma Testing

Experts from Janssen, Pharmaceutical Companies of Johnson & Johnson, discuss their validation approach and strategy for PCR-based mycoplasma testing.

ACCESS WEBINAR

PRODUCT PAGE

BIOFIRE® Mycoplasma

BIOFIRE® Mycoplasma provides simple, accurate, and rapid in-house mycoplasma detection for use in testing raw materials, in-process samples, and final product release. We offer validation services designed to meet regulatory requirements—from documentation to comprehensive on-site support.

MORE DETAILS

WHITE PAPER

Real-World Data From Cell Therapy Manufacturers

Two cell therapy manufacturers evaluated the BIOFIRE® FILMARRAY® 2.0 system for mycoplasma detection. Interested in the results? 

DOWNLOAD WHITE PAPER